Search
Returning search results with filters:
Remove filter for
Audience: Healthcare
Remove filter for
Issue: Health products
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Recall class
Displaying 196 - 210 of 905 items.
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
AlertHealth professional risk communication | 2023-01-17
Flourimax suspension: Out of specification
RecallHealth product recall | 2022-12-15
Allergenic extract non pollens (Peanut allergy): False negative for skin test
RecallHealth product recall | 2022-12-14
COMIRNATY Original & Omicron BA.4/BA.5 Bivalent Vaccine with English-only Vial and Carton Labels: New Formulation for Use in Children 5 to Less Than 12 Years of Age
AlertHealth professional risk communication | 2022-12-09
Now Kids Vitamin D-3: Out of Specification
RecallHealth product recall | 2022-12-08
NAT-Bendamustine: Discoloration
RecallHealth product recall | 2022-12-06
OCALIVA (obeticholic acid) – New Contraindication for the Treatment of Primary Biliary Cholangitis (PBC)
AlertHealth professional risk communication | 2022-12-05
Tums Peppermint Regular Strength Tablets: Foreign matter
RecallHealth product recall | 2022-12-05
Privigen: Series of adverse reactions
RecallHealth product recall | 2022-12-01
SPIKEVAX Bivalent (Original / Omicron BA.4/5) (elasomeran/davesomeran) COVID-19 Vaccine with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2022-11-18
Allergenic extract non pollens (Peanut allergy): False negative for skin test
RecallHealth product recall | 2022-11-15
Baxter Corporation; leaks of intravenous bags
RecallHealth product recall | 2022-11-03
Canadian labelling for all JAK inhibitors to include risks of serious heart-related problems, fatal blood clots and cancer
AlertPublic advisory | 2022-11-01
Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy
AlertHealth professional risk communication | 2022-10-31
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
AlertHealth professional risk communication | 2022-10-26